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S U M M A R Y
Background: Vitamin A has widespread effects on immune function and is therefore interesting in HIV-
infection. Retinol-binding protein (RBP or RBP4) is a negative acute-phase protein and a marker of
vitamin A status. Our aim was to investigate the association of RBP with HIV progression, infection with
schistosomiasis, inﬂammatory cytokines, and mortality.
Methods: The study included 192 HIV-infected and 177 HIV-uninfected individuals from Mupfure in
rural Zimbabwe. Of these, 208 were infected with Schistosoma haematobium, 27 with S. mansoni and
48 with both. Plasma RBP, HIV-RNA, CD4 cell count, haemoglobin, cytokines, clinical staging (CDC
category), self-reported level of function (Karnoffsky Performance Score, KPS) and schistosomiasis status
were assessed at baseline. Participants were followed up for survival 3-4 years post-enrolment.
Results: RBP levels were lower in HIV-infected individuals(p<0.0001). Among HIV-infected individuals,
multivariable analysis showed RBP to be positively correlated with CD4 cell count(p=0.050),
KPS(p=0.003), and haemoglobin(p<0.0001) and negatively correlated with HIV-RNA(p<0.0001), CDC
category(p<0.0001), tumor necrosis factor-receptor II(p<0.0001) and interleukin(IL)-6(p=0.004), as well
as with IL-8(p=0.005) and IL-10(p=0.003) for HIV-infected men. Furthermore, among HIV-infected
individuals RBP correlated negatively with schistosomiasis(p=0.038) and intensity of infection:
circulating anodic antigen(p=0.014), circulating cathodic antigen(p<0.0001) and faecal egg out-
put(p=0.004).
Conclusions: In HIV-infected individuals, RBP was negatively associated with levels of inﬂammatory
markers, markers of HIV progression, infection with schistosomiasis and markers of schistosomal
intensity.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id* Corresponding author. Department of Clinical Immunology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark.
E-mail address: Sebastian.ranzi.kotze@clin.au.dk (S.R. Kotze´).
http://dx.doi.org/10.1016/j.ijid.2015.01.015
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S.R. Kotze´ et al. / International Journal of Infectious Diseases 33 (2015) 159–1641601. Introduction
Retinol-binding protein 4 (RBP, also known as RBP4) is a
circulating plasma protein produced in the liver and adipose tissue
with the function of transporting vitamin A, as retinol, around the
body.1 In the context of HIV infection, vitamin A is interesting
because of the widespread inﬂuence it has on immune function.2–4
RBP is closely linked with plasma retinol and is a useful marker of
vitamin A status. Several studies have found it to predict levels of
retinol with high sensitivity and speciﬁcity, not only in healthy
individuals, but also within the context of HIV-infection, protein
malnutrition and the acute-phase response.5–8 In addition to being
cheaper and easier to measure than vitamin A, RBP is more stable,
and requires less plasma for analysis.9
RBP is also a negative acute-phase protein, with plasma levels
dropping in response to acute inﬂammation.10 This is also the case in
HIV infection, with lower plasma RBP levels reported in HIV-infected
patients compared with HIV-uninfected controls. Similarly, lower
RBP levels were found among HIV-infected individuals with an
acute-phase response when compared to HIV-infected individuals
without an acute-phase response as measured by plasma C-reactive
protein (CRP) and tumor necrosis factor (TNF)-a,8,11 however, the
association with other inﬂammatory markers, e.g. plasma levels of
cytokine and cytokine receptors: soluble TNF-receptor II (TNF-rII),
interleukin (IL)-6, IL-8 and IL-10, has yet to be investigated.
Studies of the effect of vitamin A on HIV mortality, as well as on
progression and transmission have reported mixed results, ﬁnding
both high and low vitamin A intake to be associated with higher
risk of mortality, progression and transmission.12–14 Only one
study of RBP and schistosomiasis is mentioned in the literature,
reporting infection with schistosomiasis to be associated with
lower RBP levels.15
Previous studies have shown CD4 cell count, haemoglobin level,
viral load, clinical staging and self-reported level of function to be
good markers of HIV progression, and predictors of mortality. The
aim of this study was to explore the association between RBP and
markers of disease progression and mortality in treatment-naı¨ve,
HIV-infected individuals. To study how RBP correlates with other
markers of the acute inﬂammatory response, we also investigated
associations with general markers of inﬂammation: TNF-rII, IL-6,
IL-8 and IL-10.
As the prevalence of schistosomiasis, and therefore also of dual
infection, was high in the geographical area of the current study,
another aim of the study was to examine the association of RBP
with schistosomiasis infection (with either Schistosoma haemato-
bium or Schistosoma mansoni or both) and schistosomal intensity as
measured by circulating cathodic antigen (CCA), circulating anodic




Our study population comprised 198 HIV-infected and 180 HIV-
uninfected adults (18 years old) who were naı¨ve for treatment
with anti-retroviral drugs. Previous studies have described this
cohort in detail.16,17 The study was initiated in 2001, and consisted
of participants from the Mupfure Schistosomiasis and HIV (MUSH)
cohort from Mupfure and surrounding areas of the Shamva District
in Mashonaland Central Province, Zimbabwe. Pregnant women
were not included in the study.
Examination of participants and blood sampling was conducted
from 2001 to 2004. The national ART programme was not
implemented until after the completion of the study. There was
no vitamin supplementation programme in the area and, as such,no participants received vitamin A supplementation during the
study.
Blood for RBP measurements was sampled at baseline and after
three months. Clinical status (by CDC category) and level of
function (by Karnoffsky Performance Score, KPS) were assessed by
one of the authors (PK) at baseline. In January 2006, a ﬁeld trip was
carried out to assess the survival of the participants through
personal contact with participants or their relatives or neighbours.
Participants infected with schistosomiasis at baseline were
randomized to treatment with a single dose of praziquantel
(40 mg/kg) at baseline or three months later, respectively, as
previously described.18
Oral and written informed consent was obtained from all
participants and permission to carry out the study was given by the
Provincial Medical Director of Mashonaland Central Province, the
District Medical Ofﬁcer of Shamva District, as well as village and
key community leaders.
2.2. Laboratory Analysis
Blood samples were collected in tubes coated with ethylene-
diaminetetraacetic acid. They were kept cool and plasma was
separated into cryotubes and frozen within 4 hours of collection and
stored in liquid nitrogen until shipment on dry ice. In Copenhagen,
samples were stored at 80 8C until cytokine analysis (2004),
measurement of TNF-rII (2005) or measurement of RBP levels
(2007).
Plasma RBP was measured in baseline blood samples, and in
samples drawn after three months, by enzyme-linked immuno-
sorbent assay (ELISA) as described previously.19
HIV status was determined on dry blood spots in the ﬁeld as
previously described16 (Determine, Abbott, Tokyo, Japan) and
veriﬁed by two ELISA tests carried out on serum (Recombigen,
Cambridge Biotech, Galway, Ireland; Ortho, Raritan, New Jersey,
USA). There were no conﬂicting results between tests.
HIV-RNA was determined using the Roche Amplicor HIV-1
Monitor test version 1.5 (Hoffman-La Roche, Basel, Switzerland).
CD4 cell count was determined with FacsCalibur (Becton-Dick-
inson, San Jose, California, USA).
Haemoglobin was measured by Hematology Analyzer SF3000
(Sysmex, Ramsey, Minnesota, USA).
IL-6, IL-8 and IL-10 were measured by cytometric bead array
(CBA Human Inﬂammation Kit; BD Biosciences, San Diego,
California, USA). TNF-rII levels were determined by ELISA
(Quantikine, R&D Systems, Minneapolis, Minnesota, USA).
S. haematobium was diagnosed by microscopy of urine samples
ﬁltered through Nytrel ﬁlters on three consecutive days (Vester-
gaard Frandsen, Kolding, Denmark) using the syringe urine
ﬁltration technique20 and diagnosis of S. mansoni, as well as faecal
egg output was determined using the modiﬁed formol-ether
concentration technique.21
Intensity of infection with S. haematobium and S. mansoni were
both assessed by levels of CAA and CCA measured in serum by
ELISA, as described by Polman et al.22
2.3. Statistical Analyses
Statistical analysis was performed using Stata 11.1 (StataCorp,
College Station, Texas, USA) and SAS 9.3 (SAS Institute, Cary, North
Carolina, USA). Levels of HIV-RNA, TNF-rII, IL-6, IL-8, IL-10, CAA,
CCA and faecal egg output were log10-transformed to approximate
normal distribution.
HIV and inﬂammation: RBP levels in the HIV-infected and
uninfected groups were compared using Student’s T-test. Univari-
able and multivariable regression analyses were carried out on
HIV-infected and uninfected groups with CD4 cell count, HIV-RNA,
S.R. Kotze´ et al. / International Journal of Infectious Diseases 33 (2015) 159–164 161haemoglobin, CDC-category (A was coded as 0, B as 1, and C as 2),
KPS-score and markers of inﬂammation as predictors of RBP levels.
In multivariable analyses, age, sex and infection with S.mansoni
and S. haematobium, were also included.
Schistosomiasis infection and intensity: Univariable and
multivariable regression analyses were performed with S. mansoni,
S. haematobium, CAA, CCA and faecal egg output as predictors of
RBP. Multivariable analyses were adjusted for age and sex (as well
as CD4 cell count and HIV-RNA for HIV-infected individuals). The
effect of schistosomiasis treatment on RBP levels after three
months was assessed by analysis of co-variance (ANCOVA).
All multivariable regression analyses were tested for interac-
tions between sex and predictors of RBP. Insigniﬁcant cross-
products were excluded from the analyses.
Survival: A Kaplan-Meier plot was drawn with HIV-infected
participants stratiﬁed into quartiles of RBP levels at baseline. These
groups were compared by log rank test. Multivariable proportional
hazards analysis compared survival between the RBP strata with
adjustment for CD4 cell count, HIV-RNA, age, sex and infection
with S. mansoni and S. haematobium. Interaction between RBP
strata and sex was tested, and cross-products omitted if
insigniﬁcant. Additionally, comparisons of baseline parameters
between RBP strata were made by T-test or chi-square test. The Cox
analyses were tested for proportionality by assessment of
interactions between survival time and RBP strata.
Results are medians with 25th and 75th percentiles or means,




The baseline characteristics of the cohort have previously been
described in detail.16 The cohort consisted of 378 participants,
eight of whom were excluded due to missing RBP values. This was
due to insufﬁcient plasma for laboratory analysis to be performed.
One participant was excluded because of an outlying RBP value
(5.13 mmol/l), put down to false measurement. Thus, this study
included results from 192 HIV-seropositive and 177 HIV-seroneg-
ative individuals (Table I). Finally, there were six missing
haemoglobin values, 11 missing faecal egg outputs and 44 missing
CAA values and one outlying CD4 cell count (also put down to false
measurement), and these individuals were omitted from the
statistical analyses where appropriate.
The prevalence of S. haematobium and S. mansoni in the study
population are described in more detail in a previous publication,15
and are also shown in Table 1.
3.2. HIV and inﬂammation at baseline
We found lower RBP levels among HIV-infected individuals than
among HIV-uninfected individuals (p<0.0001; mean difference:Table 1
Baseline characteristics of the cohort
HIV-infected (n=192) 
Women (n=158) Men (
RBP, mmol/l 1.20 (0.93 - 1.43) 1.40 (0
CD4 cell count, cells/ml 357 (220 - 535) 208 (1
HIV-RNA, log10copies/ml 4.69 (4.06 - 5.22) 5.14 (4
Age, years 31 (27 - 38) 32 (3
S. haematobium only 86 (52.4%) 19 (5
S. mansoni only 14 (8.5%) 3 (8
S. haematobium & S. mansoni 31 (18.9%) 3 (8
Results are medians with (25th – 75th percentiles) or numbers with (percentages).0.31 mmol/l; 95%CI: 0.22 – 0.39). There was a tendency towards
lower RBP levels in women compared with men in the HIV-infected
individuals (p=0.115), with a weaker association in the HIV-
uninfected group (p=0.223).
Using univariable regression analysis in the HIV-infected group,
RBP was found to be positively associated with haemoglobin
(p<0.0001) and KPS-group (p=0.003), and negatively associated
with HIV-RNA (p=0.001), CDC category (p=0.001), levels of TNF-rII
(p<0.0001) and IL-6 (p=0.002) (Table II). Univariable analysis
within the HIV-uninfected group showed positive correlation of
RBP with haemoglobin (p=0.007) but no correlation with the
remaining parameters. In multivariable linear regression analysis
in the HIV-infected group, there was signiﬁcant interaction
between IL-8 and sex (p=0.023) and between IL-10 and sex
(p=0.006), and therefore, the analyses for these parameters as
predictors of RBP were performed stratiﬁed by sex. We thus found
RBP to be negatively correlated with IL-8 (p=0.006) and IL-10
(p=0.002) in men. There were no interactions between sex and the
remaining predictors. Results from analyses adjusted for age, sex
and infection with S. haematobium and S. mansoni were similar
(Table 2), though there was now a signiﬁcant correlation between
RBP-levels and CD4 cell count (p=0.050).
3.3. Schistosomiasis infection and intensity at baseline
In the HIV-infected group, participants with S. mansoni had
lower RBP levels both in univariable linear regression analysis
(p=0.038) and in multivariable analysis (p=0.048). RBP levels did
not differ according to infection with S. haematobium (Table 3). In
the HIV-uninfected group, we found no association between RBP
and infection with S. mansoni or S. haematobium.
In the HIV-infected group but not in the HIV-uninfected group,
univariable analysis showed RBP to be negatively correlated with
schistosomal intensity as measured by CCA (p=0.0001), CAA
(p=0.014) and faecal egg output (p=0.004), but not with urine egg
output (p=0.559). Similar results were found in the multivariable
analyses adjusted for age and sex (as well as CD4 cell count and
HIV-RNA for HIV-infected individuals) (Table 3).
An ANCOVA showed no difference in RBP levels at the three-
month follow-up between groups who were or were not treated for
schistosomiasis at baseline, either in the HIV-infected group
(p=0.96) or in the HIV-uninfected group (p=0.86). Similarly, no
effect of treatment was found when only S. mansoni infected
participants were included in the analysis.
3.4. Survival
It was possible to obtain information on survival status for all
participants through enquiries to participants, relatives, or
neighbours.18 Among HIV-infected participants the total follow-
up time was 631 years (median 3.6 person-years, 25–75
percentiles, 3.0–4.1) and 58 deaths were recorded. Among the
causes of death reported by the relatives, diarrhoea and respiratoryHIV-uninfected (n=177)
n=34) Women (n=137) Men (n=40)
.99 - 1.61) 1.46 (1.22 - 1.74) 1.56 (1.36 - 1.81)
22 - 359) 895 (710 - 1227) 702.5 (525 - 951)
.44 - 5.42) - -
2 - 40) 29 (23 - 43) 27 (21 - 47)
5.9%) 81 (58.7%) 27 (60.5%)
.8%) 7 (5.1%) 3 (7.1%)
.8%) 12 (8.7%) 3 (7.1%)
Table 2
Linear regression analyses: inﬂammation and progression markers as predictors of retinol-binding protein
Univariable Multivariable
p RC 95% CI p RC 95% CI
HIV-infected
CD4 cell count (100cells/ml) 0.138 0.02 -0.01 0.04 0.050 0.03 0.01 0.04
HIV-RNA (log10 copies/ml) 0.001 -0.12 -0.18 -0.05 <0.0001 -0.13 -0.19 -0.06
Hemoglobin (g/dl) <0.0001 0.09 0.06 0.12 <0.0001 0.09 0.06 0.12
CDC-category ((B+C) vs. A) 0.001 -0.20 -0.31 -0.09 <0.0001 -0.20 -0.31 -0.09
KPS-group 0.003 0.14 0.05 0.23 0.003 0.15 0.05 0.24
TNF-rII (log10mg/ml) <0.0001 -0.55 -0.83 -0.28 <0.0001 -0.59 -0.87 -0.32
IL-6 (log10mg/ml) 0.002 -0.21 -0.35 -0.58 0.004 -0.20 -0.34 -0.06
IL-8 (log10mg/ml)
Women (n=158) 0.093 -0.19 -0.40 0.03 0.200 -0.14 -0.36 0.08
Men (n=34) 0.006 -0.93 -1.58 -0.59 0.005 -1.14 -1.90 -0.38
IL-10 (log10mg/ml)
Women (n=137) 0.194 -0.08 -0.21 0.04 0.234 -0.08 -0.20 0.05
Men (n=40) 0.002 -0.61 -0.98 -0.24 0.003 -0.64 -1.05 0.23
HIV-uninfected
Hemoglobin (g/dl) 0.007 0.06 0.02 0.11 0.019 0.06 0.01 0.11
KPS-group 0.487 0.10 -0.18 0.38 0.312 0.14 -0.14 0.43
TNF-rII (log10mg/ml) 0.655 -0.07 -0.38 0.24 0.510 -0.11 -0.42 0.21
IL-6 (log10mg/ml) 0.867 0.01 -0.15 0.18 0.936 0.01 -0.16 0.17
IL-8 (log10mg/ml) 0.458 -0.08 -0.30 0.14 0.499 -0.08 -0.30 0.15
IL-10 (log10mg/ml) 0.054 -0-11 -0.23 0.00 0.061 -0.11 -0.23 0.01
Results are p values with regression coefﬁcients (RC) in mmol/l and 95% conﬁdence intervals (CI).
Multivariable analysis was adjusted for age, sex and infection with S. haematobium and S. mansoni.
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Only one death was not directly attributable to HIV pathogenesis
(suicide), and for 12 deaths, the causes were not known. As
previously described, only one death was recorded among HIV-
uninfected participants, and thus only HIV-infected participants
were included in survival analyses.
The log-rank test for HIV-infected individuals showed higher
mortality among individuals in the lowest (p<0.001) but not in the
highest (p=0.134) quartiles of plasma RBP level at baseline
compared with the middle two quartiles (Figure 1). Conversely,
the multivariable Cox proportional hazards analysis adjusted for
age, sex, CD4 cell count, HIV-RNA and infection with S. mansoni and
S. haematobium at baseline showed higher mortality in the highest
quartile (HR=2.19, p=0.038) but not in the lowest (HR=1.66,
p=0.124) when compared with the middle two quartiles (Table 4).
Successive adjustment for CCA, CAA and faecal egg output did not
alter results signiﬁcantly. There were no interactions between sex
and RBP strata in any of the multivariable analyses.
There was no indication of disproportionality in univariable Cox
models (lowest quartile vs. middle quartiles: p=0.23; highestTable 3




S. mansoni 0.038 -0.14 -0.28 
S. haematobium 0.225 -0.08 -0.21 
CAA (log10 pg/ml) 0.014 -0.08 -0.14 
CCA (log10 pg/ml) <0.0001 -0.22 -0.33 
Fecal egg output (log10 pg/ml) 0.004 -0.29 -0.49 
Urine egg output (log10 pg/ml) 0.559 -0.02 -0.09 
HIV-uninfected
S. mansoni 0.117 -0.13 -0.30 
S. haematobium 0.552 0.04 -0.09 
CAA (log10 pg/ml) 0.354 -0.04 -0.12 
CCA (log10 pg/ml) 0.169 -0.06 -0.15 
Fecal egg output (log10 pg/ml) 0.179 -0.24 -0.60 
Urine egg output (log10 pg/ml) 0.794 -0.01 -0.08 
Results are p values with Regression Coefﬁcients (RC) in mmol/l and 95% conﬁdence in
Multivariable analysis was adjusted for age and sex. For HIV-infected individuals, CD4quartile vs. middle quartiles: p=0.69) or in multivariable models
(lowest quartile vs. middle quartiles: p=0.15; highest quartile vs.
middle quartiles: p=0.87).
To investigate whether the higher mortality among individuals
with high RBP levels could be explained by confounders, we
compared the baseline characteristics of individuals in the lowest
and highest quartiles of baseline RBP with individuals in the
middle two quartiles combined. We found that individuals in the
lowest quartile of RBP had lower CD4 cell count (p=0.043, mean
difference, middle quartiles – lowest quartile: 83 cells/ml, 95%CI:
3-163) and higher HIV RNA (p=0.020, mean difference, middle
quartiles – lowest quartile: 0.36 log10 copies/ml, 95%CI: 0.06-0.66).
Individuals in the highest quartile of RBP did not have lower CD4
cell count (p=0.993, mean difference, middle quartiles – highest
quartile: 0 cells/ml, 95%CI: -88-89) or higher HIV RNA (p=0.158,
mean difference, middle quartiles – highest quartile: 0.23 log10-
copies/ml, 95%CI: -0.09-0.54) compared with the middle two
quartiles combined. Individuals in different RBP quartiles did not
differ with regard to haemoglobin, age or distribution of sex, S.
haematobium, or S. mansoni.Multivariable
95% CI p RC 95% CI
-0.01 0.048 -0.13 -0.27 -0.001
0.05 0.153 -0.09 -0.22 0.04
-0.02 0.029 -0.07 -0.13 -0.01
-0.12 0.001 -0.18 -0.29 -0.08
-0.10 0.002 -0.31 -0.51 -0.12
0.05 0.561 -0.02 -0.09 0.05
0.03 0.206 -0.11 -0.28 0.06
0.16 0.350 0.06 -0.07 0.19
0.04 0.645 -0.02 -0.10 0.06
0.03 0.294 -0.05 -0.14 0.04
0.11 0.241 -0.21 -0.57 0.15
0.06 0.684 0.02 -0.06 0.09
tervals (CI).




Quartile p HR 95% CI p HR 95% CI
1st 0.001 2.73 1.48 - 5.04 0.124 1.66 0.87 - 3.17
2nd+3rd - 1.0 - - 1.0 -
4th 0.138 1.67 0.85 - 3.29 0.038 2.19 1.04 - 4.60
Results are p values with hazard ratios (HR) and 95% conﬁdence intervals (CI).
The multivariable analysis was adjusted for age, sex, CD4 cell count, HIV-RNA and


















0 1 2 3 4
Follow-up (years)
Figure 1. Kaplan-Meier plots of survival among HIV-positive individuals stratiﬁed
by plasma RBP levels at baseline. Survival time was calculated from baseline to
death or censoring. Comparison of 1st (lowest) quartile of RBP vs. 2nd and 3rd
combined: p<0.01 by log rank test. Comparison of 4th (highest) quartile of RBP vs.
2nd and 3rd combined: p=0.13 by log rank test.
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The plasma RBP levels found among volunteers in this cohort
were higher compared to levels reported in a previous study from
Kenya, both in HIV-infected (1.23 mmol/l vs. 0.9 mmol/l) and HIV-
uninfected individuals (1.54 mmol/l vs. 1.10 mmol/l)8. In both
studies, participants were naı¨ve to antiretroviral treatment.
However, the HIV-infected participants in the study by Baeten
et al had higher HIV-RNA levels and lower CD4 cell counts (HIV-
RNA: 5.4 log10copies/ml; CD4 cell count: 226 cells/ml) compared to
individuals in the MUSH cohort (HIV-RNA: 4.6 log10copies/ml; CD4
cell count: 370 cells/ml). Several studies have used cut-off values of
between 0.7 and 0.8 mmol/l RBP to predict vitamin A-deﬁciency,
deﬁned as plasma retinol<0.7 mmol/l,23 with high sensitivity and
speciﬁcity. Using a cut-off value for RBP of 0.8 mmol/l, we found 29
(27 HIV-infected, 2 HIV-uninfected) individuals to have decreased
levels of RBP, indicative of vitamin A-deﬁciency, compared with
normal, healthy individuals. This corresponds to 14% of HIV-
infected individuals and just 1% of HIV-uninfected individuals,
while the Kenyan study found vitamin A-deﬁciency in 26% of HIV-
infected and 6% of HIV-uninfected participants.8
Lower RBP levels among HIV-infected individuals may adhere
to RBP and retinol being negative markers of the acute-phase
response, but it is possible that protein malnutrition in the later
stages of the disease may also contribute to lower levels of RBP.8,24
Participants’ retinol levels were not measured due to insufﬁcient
remaining plasma. However, because of the close association
between RBP and retinol documented by recent studies,5–8 we ﬁnd
it reasonable to expect similar correlations between RBP and
retinol in our study.In accordance with studies describing RBP as a negative marker
of the acute-phase inﬂammatory response,8 we found RBP to be
negatively correlated with markers of inﬂammation (TNF-receptor
level, IL-6, IL-8, IL-10) as well as with HIV-RNA and clinical staging
(CDC-category). However, the factor most closely correlated with
RBP, in both HIV-infected and HIV-uninfected groups, was
haemoglobin. This is interesting, though not unexpected, since
vitamin A supplementation has been shown to increase levels of
haemoglobin25 and that RBP, vitamin A and haemoglobin levels are
affected by malnutrition, a common complication of HIV-infec-
tion.26
We found that infection with S. mansoni was closely associated
with low RBP levels in the HIV-infected group. Earlier studies have
also reported lower levels of RBP in schistosoma-infected
individuals though these were not co-infected with HIV.15,27
Interestingly, another study found S. mansoni faecal egg output, but
not S. haematobium urine egg output to be associated with lower
retinol levels, which is consistent with our results.28 However, we
also showed that schistosoma intensity measured as CAA and CCA
correlated negatively with RBP, but only among HIV-infected
individuals. CAA and CCA are generally higher in S. mansoni
infections and may reﬂect intensity better in S. mansoni infection
than in infection with S. haematobium. This may result in a stronger
negative correlation between RBP and intensity in S. mansoni
infection than in S. haematobium infection, however this does not
explain why this association was only found in HIV-infected
individuals. We speculate that this could be due to the effect of
vitamin A on enteric mucosal immunity: retinoic acid stimulates
the differentiation of regulatory T-helper cells and up-regulates
gut-homing receptors, by which T- and B-cell responses are
targeted to gut-associated lymphoid tissue (GALT).29 We propose
that decreased vitamin A may thus result in increased severity of
infection with S. mansoni, which is located in the blood vessels of
the colon wall, in contrast to S. haematobium, which resides in
bladder associated vessels. In addition to this, GALT is known to be
severely damaged during acute HIV infection,30 providing a
possible explanation for why signiﬁcant association between
RBP and S. mansoni was only seen in the HIV-infected group.
Treatment for schistosomiasis did not affect RBP levels, suggesting
that schistosomiasis did not decrease RBP levels, but rather that
low RBP levels may have facilitated and increased the severity of
schistosomiasis infection.
In the current study, univariable analysis showed low levels of
RBP to be associated with increased mortality among HIV-infected
participants, whereas we only found this association as a tendency
in the multivariable analysis. Participants with low RBP had higher
levels of HIV-RNA and lower CD4 counts than participants with
higher RBP levels. Thus increased mortality among participants in
the lowest quartile of RBP in the univariable analysis may adhere to
more progressed HIV infection among these individuals. We also
found high RBP to be associated with increased mortality, and this
was found to be independent from adjustments for CD4 cell count
and HIV-RNA. A study carried out in the United States by Tang et al
reported an increased risk of progression to AIDS and higher
mortality among HIV-infected individuals with high as well as low
vitamin A intake.13,14 Our results, while they corroborate this
previous study, unfortunately offer no explanation for this
observation. We can speculate that high vitamin A levels may
affect disease progression by increasing viral replication both
directly, by interacting with the virus itself,31 or indirectly by
stimulating lymphocyte proliferation, including those positive for
CCR5 receptors, increasing the number of potential host cells.32
However, as seen in Figure 1, the increased mortality among
individuals in the highest quartile of RBP only became evident
2.5 years after baseline, and the data in this study provides no
apparent explanation for this observation.
S.R. Kotze´ et al. / International Journal of Infectious Diseases 33 (2015) 159–164164Multiple comparisons were made in this study, however as
analysis of predictors of RBP did not show contradictory results for
any parameters in the baseline analysis, and given that the focus of
this study was hypothesis generation, it was not considered
necessary to make adjustments for multiple comparisons. The
sample sizes of the groups were not large, and thus, some of the
conﬁdence intervals we found were broad and would have
beneﬁtted from a larger number of participants, e.g. the association
of RBP with CD4 cell count in the multivariable analysis. However,
the groups were large enough to detect statistically signiﬁcant
associations in several of the analyses.
We found that RBP was lower in HIV-infected individuals
infected with S. mansoni and further decreased with schistosomi-
asis intensity. RBP had strong negative correlations with inﬂam-
matory mediators, as well as with markers of disease progression
and clinical status among individuals infected with HIV and in
accordance with these ﬁndings mortality tended to be higher
among participants with low RBP. However, in adjusted analysis,
mortality was higher among individuals with high plasma RBP at
baseline.
Acknowledgments
We thank the Mupfure Community; the Village Health Work-
ers; the Environmental Health Technician; the technical team of
E.N. Kurewa, N. Taremeredzwa, W. Mashange, C. Mukahiwa, S.
Nyandoro, W. Soko, B. Mugwagwa, and E. Mashiri; the Department
of Haematology at Parirenyatwa Hospital (R. Maﬁrakureba, D.
Mawire and B. Mudenge); and the Department of Virology at
Rigshospitalet, Copenhagen (M. Luneborg-Nielsen). The study was
funded by grants from the Danish National Research Foundation
(2117-05-0147); the Danish AIDS Foundation (F01-18, F01-19);
Fonden Til Lægevidenskabens Fremme; the DANIDA Health
Programme in Zimbabwe (2001); the Centre for Inﬂammation
and Metabolism (Danish National Research Foundation DG 02-
512-555); and the Cluster of International Health, Copenhagen
University. Funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
The authors have read and complied with the journal’s policy on
ethical consent. The study was approved by the Medical Research
Council of Zimbabwe (MRCZ/A/918) and the Central Medical
Scientiﬁc Ethics Committee of Denmark (624-01-0031).
Conﬂict of interest: The authors declare that no competing
interests exist.
References
1. Goodman DS. Plasma retinol-binding protein. Ann N Y Acad Sci 1980;348:
378–90.
2. Semba RD. Vitamin A, Immunity, and Infection. Clinical Infectious Diseases
1994;19(3):489–99.
3. Stephensen CB. Vitamin A, infection, and immune function. Annu Rev Nutr
2001;21:167–92.
4. Rumore MM. Vitamin A as an immunomodulating agent. Clin Pharm 1993 Jul;
12(7):506–14.
5. Gamble MV, Ramakrishnan R, Palafox NA, Briand K, Berglund L, Blaner WS.
Retinol binding protein as a surrogate measure for serum retinol: studies in
vitamin A–deﬁcient children from the Republic of the Marshall Islands. The
American Journal of Clinical Nutrition 2001 Mar 1;73(3):594–601.
6. Almekinder J, Manda W, Soko D, Lan Y, Hoover DR, Semba RD. Evaluation of
plasma retinol-binding protein as a surrogate measure for plasma retinol
concentrations. Scand J Clin Lab Invest 2000 May;60(3):199–203.7. Semba RD, Yuniar Y, Gamble MV, Natadisastra G, Muhilal. Assessment of
vitamin A status of preschool children in Indonesia using plasma retinol-
binding protein. J Trop Pediatr 2002 Apr;48(2):84–7.
8. Baeten JM, Richardson BA, Bankson DD, Wener MH, Kreiss JK, Lavreys L, et al.
Use of serum retinol-binding protein for prediction of vitamin A deﬁciency:
effects of HIV-1 infection, protein malnutrition, and the acute phase response.
Am J Clin Nutr 2004 Feb;79(2):218–25.
9. Gorstein JL, Dary O, Pongtorn null, Shell-Duncan B, Quick T, Wasanwisut E.
Feasibility of using retinol-binding protein from capillary blood specimens to
estimate serum retinol concentrations and the prevalence of vitamin A deﬁ-
ciency in low-resource settings. Public Health Nutr 2008 May;11(5):513–20.
10. Fleck A. Clinical and Nutritional Aspects of Changes in Acute-Phase Proteins
During Inﬂammation. Proceedings of the Nutrition Society 1989;48(03):347–54.
11. Neves FF, Figueiredo JF, de C, Jorda˜o Ju´nior AA, Vannucchi H. [Inﬂuence of acute-
phase inﬂammatory response on serum levels of retinol and retinol binding
protein in HIV/AIDS patients]. Rev Soc Bras Med Trop 2010 Feb;43(1):23–6.
12. Mehta S, Fawzi W. Effects of vitamins, including vitamin A, on HIV/AIDS
patients. Vitam Horm 2007;75:355–83.
13. Tang AM, Graham NM, Kirby AJ, McCall LD, Willett WC, Saah AJ. Dietary
micronutrient intake and risk of progression to acquired immunodeﬁciency
syndrome (AIDS) in human immunodeﬁciency virus type 1 (HIV-1)-infected
homosexual men. Am J Epidemiol 1993 Dec 1;138(11):937–51.
14. Tang AM, Graham NMH, Saah AJ. Effects of Micronutrient Intake on Survival in
Human Immunodeﬁciency Virus Type 1 Infection. American Journal of Epidemi-
ology 1996 Jun 15;143(12):1244–56.
15. Stu¨rchler D, Holzer B, Hanck A, Degre´mont A. The inﬂuence of schistosomiasis
on the serum concentrations of retinol and retinol binding protein of a rural
population in Liberia. Acta Trop 1983 Sep;40(3):261–9.
16. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Erikstrup C, et al.
Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coin-
fection for excretion of eggs. J Infect Dis 2005 Apr 15;191(8):1311–20.
17. Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, et al.
Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J
Acquir Immune Deﬁc Syndr 2007 Apr 1;44(4):478–83.
18. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, Mudenge B, van Dam GJ, et al.
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of
schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis
2005 Dec 1;192(11):1956–61.
19. Erhardt JG, Estes JE, Pfeiffer CM, Biesalski HK, Craft NE. Combined measurement
of ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive
protein by an inexpensive, sensitive, and simple sandwich enzyme-linked
immunosorbent assay technique. J Nutr 2004 Nov;134(11):3127–32.
20. Mott KE, Baltes R, Bambagha J, Baldassini B. Field studies of a reusable
polyamide ﬁlter for detection of Schistosoma haematobium eggs by urine
ﬁltration. Tropenmed Parasitol 1982 Dec;33(4):227–8.
21. Knight WB, Hiatt RA, Cline BL, Ritchie LS. A modiﬁcation of the formol-ether
concentration technique for increased sensitivity in detecting Schistosoma
mansoni eggs. Am J Trop Med Hyg 1976 Nov;25(6):818–23.
22. Polman K, Diakhate MM, Engels D, Nahimana S, Van Dam GJ, Falca˜o Ferreira ST,
et al. Speciﬁcity of circulating antigen detection for schistosomiasis mansoni in
Senegal and Burundi. Trop Med Int Health 2000 Aug;5(8):534–7.
23. de Pee S, Dary O. Biochemical Indicators of Vitamin A Deﬁciency: Serum Retinol
and Serum Retinol Binding Protein. J Nutr 2002;132(9):2895S–901S.
24. Eley BS, Sive AA, Abelse L, Kossew G, Cooper M, Hussey GD. Growth and
micronutrient disturbances in stable, HIV-infected children in Cape Town.
Ann Trop Paed 2002 Mar;22(1):19–23.
25. Jimenez C, Leets I, Puche R, Anzola E, Montilla R, Parra C, et al. A single dose
of vitamin A improves haemoglobin concentration, retinol status and phago-
cytic function of neutrophils in preschool children. Br J Nutr 2010 Mar;103(6):
798–802.
26. Dunn JM. Nutritional abnormalities in HIV/AIDS. HIV Hotline 1998 May;8(2):
11–2.
27. Mikhail MM, Mansour MM. The interaction of zinc and vitamin A in human
schistosomiasis. Eur J Clin Invest 1982 Aug;12(4):345–50.
28. Friis H, Ndhlovu P, Kaondera K, Sandstro¨m B, Michaelsen KF, Vennervald BJ,
et al. Serum concentration of micronutrients in relation to schistosomiasis and
indicators of infection: a cross-sectional study among rural Zimbabwean
schoolchildren. Eur J Clin Nutr 1996 Jun;50(6):386–91.
29. Mora JR, Iwata M, von Andriano UH. Vitamin effects on the immune system:
vitamins A and D take centre stage. Nat Rev Immunol 2008 Sep;8(9):685–98.
30. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune
system. Mucosal Immunol 2008 Jan;1(1):23–30.
31. Turpin JA, Vargo M, Meltzer MS. Enhanced HIV-1 replication in retinoid-treated
monocytes. Retinoid effects mediated through mechanisms related to cell
differentiation and to a direct transcriptional action on viral gene expression.
J Immunol 1992 Apr 15;148(8):2539–46.
32. Moore JP, Klasse PJ. HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1
complex. Cell Host Microbe 2007 Nov 15;2(5):281–3.
